Rare Victory In Fight Against Melanoma
Patients with advanced melanoma rarely live for more than a year after their diagnosis–a prognosis that has not improved for more than 30 years. But clinical-trial results now suggest that a genetically targeted approach could slow the disease’s steady march through the body, and separate research reveals why the latest drug being tested may succeed where others failed.The drug could be the first melanoma treatment to join an elite but expanding list of cancer therapies tailored to a patient’s genetic make-up....